Published: Jan. 1, 2025
Language: Английский
Citations
0Emerging Role of Gut Microbiota in Breast Cancer Development and Its Implications in Treatment
Metabolites, Journal Year: 2024, Volume and Issue: 14(12), P. 683 - 683
Published: Dec. 5, 2024
Background: The human digestive system contains approximately 100 trillion bacteria. gut microbiota is an emerging field of research that associated with specific biological processes in many diseases, including cardiovascular disease, obesity, diabetes, brain rheumatoid arthritis, and cancer. Emerging evidence indicates the affects response to anticancer therapies by modulating host immune system. Recent studies have explained a high correlation between breast cancer: dysbiosis cancer may regulate systemic inflammatory response, hormone metabolism, tumor microenvironment. Some bacteria are related estrogen which increase or decrease risk changing number hormones. Further, has been seen modulate respect its ability protect against treat cancers, focus on receptor-positive Probiotics other claiming control microbiome bacterial means might be useful prevention, even treatment, Conclusions: present review underlines various aspects clinical application, warranting individualized microbiome-modulated therapeutic approaches treatment.
Language: Английский
Citations
3The Genomic and Biologic Landscapes of Breast Cancer and Racial Differences
International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(23), P. 13165 - 13165
Published: Dec. 7, 2024
Breast cancer is a significant health challenge worldwide and the most frequently diagnosed among women globally. This review provides comprehensive overview of breast biology, genomics, microbial dysbiosis, focusing on its various subtypes racial differences. primarily classified into carcinomas sarcomas, with constituting cases. Epidemiology risk factors are important for public intervention. Staging grading, based TNM Nottingham grading systems, respectively, crucial to determining clinical outcome treatment decisions. Histopathological include in situ invasive carcinomas, such as ductal carcinoma (IDC) lobular (ILC). The explores molecular subtypes, including Luminal A, B, Basal-like (Triple Negative), HER2-enriched, delves cancer's histological progression patterns. Recent research findings related nuclear mitochondrial genetic alterations, epigenetic reprogramming, role microbiome dysbiosis differences also reported. an update current diagnostics modalities.
Language: Английский
Citations
3Case report: Primary CDK4/6 inhibitor and endocrine therapy in locally advanced breast cancer and its effect on gut and intratumoral microbiota
Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14
Published: March 27, 2024
Locally advanced breast cancer poses significant challenges to the multidisciplinary team, in particular with hormone receptor (HR) positive, HER2-negative tumors that classically yield lower pathological complete responses chemotherapy. The increasingly use of CDK 4/6 inhibitors (CDK4/6i) plus endocrine therapy (ET) different settings has led clinical trials focusing on this strategy as a primary treatment, promising results. impact microbiota cancer, and vice-versa, is an emerging topic oncology. authors report case postmenopausal female patient invasive carcinoma right breast, Luminal B-like, staged cT4cN3M0 (IIIB). Since lesion was considered primarily inoperable, started letrozole ribociclib. Following 6 months systemic therapy, response significant, surgery curative intent performed. final staging ypT3ypN2aM0, R1, adjuvant radiotherapy. This provides important insights CDK4/6i ET locally unresectable HR+/HER2- its potential implications disease management further ahead. patient’s gut analyzed throughout course therapeutic approach, evidencing shift microbial dominance from Firmicutes Bacteroidetes loss diversity following therapy. analysis intratumoral surgical specimen revealed high dissimilarity between residual tumor respective margins.
Language: Английский
Citations
2Fusobacterium nucleatum: An Overview of Evidence, Demi-Decadal Trends, and Its Role in Adverse Pregnancy Outcomes and Various Gynecological Diseases, including Cancers
Cells, Journal Year: 2024, Volume and Issue: 13(8), P. 717 - 717
Published: April 20, 2024
Gynecological and obstetric infectious diseases are crucial to women’s health. There is growing evidence that links the presence of Fusobacterium nucleatum (F. nucleatum), an anaerobic oral commensal potential periodontal pathogen, development progression various human diseases, including cancers. While role this opportunistic pathogen has been extensively studied in colorectal cancer recent years, research on its epidemiological mechanistic link gynecological (GDs) still ongoing. Thus, present review, which first kind, aims undertake a comprehensive critical reappraisal F. nucleatum, genetics promoting adverse pregnancy outcomes (APOs) GDs, Additionally, review discusses new conceptual advances immunomodulatory breast, ovarian, endometrial, cervical carcinomas through activation direct indirect signaling pathways. However, further studies needed explore elucidate highly dynamic process host–F. interactions discover pathways, will pave way for better preventive therapeutic strategies against pathobiont.
Language: Английский
Citations
2Induction of Cell Death by Bifidobacterium infantis DS1685 in Colorectal and Breast Cancers via SMAD4/TGF-Beta Activation
Journal of Microbiology and Biotechnology, Journal Year: 2024, Volume and Issue: 34(8), P. 1698 - 1704
Published: July 12, 2024
Language: Английский
Citations
2Microbiome—Stealth Regulator of Breast Homeostasis and Cancer Metastasis
Cancers, Journal Year: 2024, Volume and Issue: 16(17), P. 3040 - 3040
Published: Aug. 31, 2024
Cumulative evidence attests to the essential roles of commensal microbes in physiology hosts. Although microbiome has been a major research subject since time Luis Pasteur and William Russell over 140 years ago, recent findings that certain intracellular bacteria contribute pathophysiology healthy vs. diseased tissues have brought field new era investigation. Particularly, breast cancer research, breast-tumor-resident are now deemed be players tumor initiation progression. This is resurrection Russel's bacterial cause theory, which was fact abandoned 100 ago. review will introduce some exemplify carcinogenesis metastasis provide mechanistic explanations for these phenomena. Such information would able justify utility as biomarkers disease progression therapeutic targets.
Language: Английский
Citations
2ANTITUMOR EFFECTIVENESS OF THE COMBINED APPLICATION OF BACTERIA OF THE GENUS BIFIDOBACTERIUM AND B. SUBTILIS IMV B-7724 LECTIN
Oncology, Journal Year: 2024, Volume and Issue: 26(2), P. 133 - 138
Published: Jan. 1, 2024
Summary. Aim: to investigate of the antitumor effectiveness combined use bacteria genus Bifidobacterium and extracellular metabolite (lectin) B. subtilis IMV B-7724. Object methods: studies were performed on Balb/c mice (n = 52). Ehrlich adenocarcinoma was used as an experimental model. Starting from 2nd day after transplantation tumor cells, animals groups injected with lectin B-7724 (s/c, 1 mg/kg body weight, No. 10), animalis (per os, 7×105 CFU/ mouse, 10) or their combination. The frequency (%), latent period emergence, volume tumors (mm3), life expectancy evaluated. Statistical processing results carried out according generally accepted methods variational statistics. Results: administration IMB (both alone in combination animalis) resulted a significant inhibition growth. growth index 55.0 50.5%, respectively. these also characterized by statistically increase compared control group: 61.4 50.0%, did not have such pronounced effect. Conclusion: model, effect (inhibition primary growth, expectancy), both lectin, separate bacterial demonstrated. affect dynamics animals.
Language: Английский
Citations
1Tumor-on-chip platforms for breast cancer continuum concept modeling
Frontiers in Bioengineering and Biotechnology, Journal Year: 2024, Volume and Issue: 12
Published: Oct. 2, 2024
Our previous article entitled "Proteomics and its applications in breast cancer", proposed a Breast Cancer Continuum Concept (BCCC), including Cell as well Proteomic Concept. cancer-on-chip (BCoC), cancer liquid biopsy-on-chip (BCLBoC), metastasis-on-chip (BCMoC) models successfully recapitulate reproduce
Language: Английский
Citations
1Metabolites in the Dance: Deciphering Gut-Microbiota-Mediated Metabolic Reprogramming of the Breast Tumor Microenvironment
Cancers, Journal Year: 2024, Volume and Issue: 16(24), P. 4132 - 4132
Published: Dec. 11, 2024
Breast cancer (BC), a major cause of death among women worldwide, has traditionally been linked to genetic and environmental factors. However, emerging research highlights the gut microbiome’s significant role in shaping BC development, progression, treatment outcomes. This review explores intricate relationship between microbiota breast tumor microenvironment, emphasizing how these microbes influence immune responses, inflammation, metabolic pathways. Certain bacterial species either contribute or hinder progression by producing metabolites that affect hormone metabolism, system pathways, cellular signaling. An imbalance bacteria, known as dysbiosis, associated with heightened risk BC, like short-chain fatty acids (SCFAs) enzymes such β-glucuronidase playing key roles this process. Additionally, can impact effectiveness chemotherapy, certain bacteria degrade drugs gemcitabine irinotecan, leading reduced efficacy. Understanding complex interactions may pave way for innovative approaches, including personalized microbiome-targeted therapies, probiotics fecal transplants, offering new hope more effective prevention, diagnosis, BC.
Language: Английский
Citations
1